Amiselimod (MT-1303), a Novel Sphingosine 1-Phosphate Receptor-1 Modulator, Potently Inhibits the Progression of Lupus Nephritis in Two Murine SLE Models

DOP48 Amiselimod, a selective S1P receptor modulator in Crohn’s disease patients: a proof-of-concept study

(2019) G D’Haens et al.   Journal of Crohns & Colitis

Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

(2019) Kristian Reich et al.   LANCET

Amiselimod (MT-1303), a novel sphingosine 1-phosphate receptor-1 functional antagonist, inhibits progress of chronic colitis induced by transfer of CD4+CD45RBhigh T cells

(2019) Kyoko Shimano et al.   PLoS One

Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus

(2018) Kristen R. Taylor Meadows et al.   PLoS One

Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus

(2018) Takayuki Katsuyama et al.   Frontiers in Immunology

Pharmacokinetics, Pharmacodynamics, Tolerability, and Food Effect of Cenerimod, a Selective S1P1 Receptor Modulator in Healthy Subjects

(2017) Pierre-Eric Juif et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk

(2016) Kunio Sugahara et al.   BRITISH JOURNAL OF PHARMACOLOGY

Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial

(2016) Ludwig Kappos et al.   LANCET NEUROLOGY

Beyond pan-B-cell-directed therapy — new avenues and insights into the pathogenesis of SLE

(2016) Thomas Dörner et al.   Nature Reviews Rheumatology

Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis

(2016) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis

(2015) L. Kappos et al.   NEUROLOGY

Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

(2014) Ian N Bruce et al.   ANNALS OF THE RHEUMATIC DISEASES

Treat-to-target in systemic lupus erythematosus: recommendations from an international task force

(2014) Ronald F van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

Expanded Double Negative T Cells in Patients with Systemic Lupus Erythematosus Produce IL-17 and Infiltrate the Kidneys

(2014) J. C. Crispin et al.   JOURNAL OF IMMUNOLOGY

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

(2014) Richard G. Langley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Urinary Neutrophil Gelatinase-Associated Lipocalin Is a Potential Biomarker for Renal Damage in Patients with Systemic Lupus Erythematosus

(2012) Chun-Chen Yang et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

(2011) Sandra V Navarra et al.   LANCET

Abnormalities of T cell signaling in systemic lupus erythematosus

(2011) Vaishali R Moulton et al.   ARTHRITIS RESEARCH & THERAPY

FTY720 exerts a survival advantage through the prevention of end-stage glomerular inflammation in lupus-prone BXSB mice

(2010) Seiichiro Ando et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-β in mouse experimental autoimmune encephalomyelitis

(2010) Kenji Chiba et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

CXCR3 Mediates Renal Th1 and Th17 Immune Response in Murine Lupus Nephritis

(2009) O. M. Steinmetz et al.   JOURNAL OF IMMUNOLOGY

Increased survival and reduced renal injury in MRL/lpr mice treated with a novel sphingosine-1-phosphate receptor agonist

(2008) Scott E. Wenderfer et al.   KIDNEY INTERNATIONAL

Systemic Lupus Erythematosus

(2008) Anisur Rahman et al.   NEW ENGLAND JOURNAL OF MEDICINE